Key facts
- Aspen Neuroscience and Bambusa Therapeutics launched their US IPO roadshows on Monday.
- Aspen is developing therapies for neurodegenerative diseases, including Parkinson's.
- Bambusa is developing drugs for immunological and inflammatory disorders.
- Both companies are marketing 9.38 million shares each.
- The IPO price range for both is $15 to $17 per share.
- Aspen will trade as "ASPE" on Nasdaq, Bambusa as "BBTX."
Aspen Neuroscience and Bambusa Therapeutics began their US initial public offering roadshows on Monday, joining a growing number of biotech companies seeking to capitalize on the fall IPO market. The biotech sector has been a strong performer this year, offering investors potential returns driven by clinical catalysts even amid economic uncertainty and higher interest rates. Aspen is developing treatments for neurodegenerative diseases, including Parkinson's, while Bambusa focuses on immunological and inflammatory disorders. Both companies are offering 9.38 million shares at a price between $15 and $17 each. Aspen will be listed as "ASPE" on Nasdaq, and Bambusa as "BBTX."